Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578734 · ClinicalTrials.gov registry record · Phase 2
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00578734 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 165 participants.
The verdict
NCT00578734, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).
Interventions
- OTHER Sham Comparator
- DRUG Lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578734
The ClinicalTrials.gov registry entry for NCT00578734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT00578734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578734 about?
NCT00578734 is a clinical study titled "Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old". Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs ...
What is the current status of trial NCT00578734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2007-06. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00578734?
The interventions under investigation include: Sham Comparator (OTHER), Lucinactant (DRUG).
Who is sponsoring clinical trial NCT00578734?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.